Thanks for explaining your background.It impresses and is not to be scoffed at. That you in particular originally invested in GALT stands as a superior recommendation.
What activated my skepticism towards your mounting derision of Dr. Traber et al. was your making an issue of the Alpha-2-macroglobulin protein that showed a response to GR-MD-02 in Phase1 (Cohort3). On 10/19/16 (# 2558)you say that to not include alpha-2-macroglobulin as a part of the FX protocol makes no sense whatsoever. To that assertion another writer immediately concurred with a single word ("exactly")(post# 2559). Such exactitude.
But that protein carries no validation credentials, which begs for further research (nontrivial) well outside of GALT's plans.
Alpha-2-macroglobulin is metabolically complex, multifunctional in cells. It is with good reason Dr. Traber didn't proffer it as a marker in FX. Immediately it would have been dismissed out of hand by the GALT team.
My point is that contra-you (and contra-"exactly") the deduction that omission of Alpha-2-macroglobulin from the FX trial "makes no sense whatsoever" is invalid. (Incidentally, GALT (like other companies ) consults with the FDA for guidance in trial planning).
I deduce good sense all told.
What Dr. Traber did was not care to explain. To me that's a failing only in public relations. To ascribe his style to illogic or something devious is needlessly corrosive.
Net result for me: Dr. Traber et al. remain a high-quality team, and Dr. Traber's writings and presentations indicate competence and a measured perspective.
PS: It can be easily seen that GALT's recent adjustment regarding psoriasis is credible in its fiduciary context. To assert that it's indicative of corporate disorder, as you imply, is unwarranted, not needed, resembles hitting a man when he is down.
PS#2: Please see Ricky ricks (10/22/16 # 2566) for his peachy perspective on GALT. Count me in his camp. He deserves good beer.
